





Impact of Clini	cal Issues	Week
Nutritional Risk		
Disease severity	NEW	← ICU →
Nutritional status		
Timing of nutritional intervent	ion	
First week		
Argument to AVOID fee	ding	
Height of dz process	, inflammat, insulin	resist, intolerance
Evidence that full fee	eds may be harmful	
Importance of prese	rving autophagy	
Teleologic argument	disrupting fight/fri	ght/flight response
Opposing argument to I	PROVIDE feeding	
Window of opportun	ity to attenuate dise	ease severity, SIRS
Provide non-nutrition	nal benefits of nutri	tion Rx
Second week - Change in	priorities, less contr	oversial
Need for nutritional be	nefits, impact of inc	reasing caloric deficit
latrogenic underfeedin		


Outcome: Infections Early EN vs No Ear	ly EN (p=0.01)
Early EN Delayed/None Bok Ratio	Rvk Ratio
Study or Subgroup Events Total Events Total Weight 8-H, Random, 85% CI Year	B-K, Randen, MM-CI
Sagar 1970 0 15 5 16 0.9% 0.00 (0.17, 2.07) 1970	Malue of EM
Bloom 1985 3 32 8 31 3.3% 0.32 (0.10, 1.00) 1985 *	Value of EN
Schoeder 1991 1 10 0 10 0.5% 3.00 (0.1, 0.0, 17) 1001 Cav 1991 0 11 3 14 0.0% 0.11 0.01, 213 1000	
Carr 1991 0 11 0 14 0.0% 0.14 (0.01, 2.53) 1000 1 Exter-Robuster 1960 2 30 15 30 2.0% 0.15 (0.04, 0.07) 1000 1	
Single 1990 7 21 12 22 7.0% 0.01 0.30 100 1	in the Literature:
Weard 2000 6 12 7 16 0.9% 1.07 0.44, 2.34 2000	
Bellete 2005 44 100 67 100 2005 001 054 101 1004	The formation of the second seco
Kompan 2005 9 27 16 25 9.4% 0.52 0.31 0.94 2004	Infection
Feds 2004 12 18 11 13 172% 101 024, 138 2004	+
Ngays 2000 0 14 6 14 0.0% 0.00 (0.16, 1.8% 2000	Montality
Blooks 2009 17 29 19 30 14.0% 0.93 (0.01, 1.34) 2009	- Mortality
Citoxindake 2012 13 34 12 25 93% 030 (0.44, 1.44) 2012	
Term (1996 CE) 280 280 180.9% 0.74 (0.41, 0.32)	•
Total exects IOU 191	
Heteropenenity: Tax ² = 0.05,CAP = 19,59, cf = 12 (P = 0.03); P = 30% Tentfor compile flect Z = 2.54 (P = 0.01)	
141107 00400416 (C 2 * 204 (F * 0.01)	
	Outcome: Montality Early EN vs No Early EN (p=0.05)
Infection 54 70/ 00 00/ 000	Early En to no Early En (p=0.00)
Infection 51.7%→36.3%, p=0.03	Laty18 Delgoriflese RokTato ElokTato
	Studyer lidigeng Taunts Ind Lunte Intd Weige Mill.Runden 17: 12 Tag Mill.Runden 17: 12
	Depar 13/3 0 15 0 15 Nid edimatris 15/9
	Depar 1979 0 15 E 15 Not extended 1373
	Digger (17) 0 15 Not extension (157) Mass 108 1 2 21 25 271 278
	Digst 1717 0 15 0 15 Note estimate 1717 Mana 1768 1 2 2 32.75 150.76 170.85 Chand 1760 0 0 6 16 Note estimate 170.7 100.16 Chand 1760 0 0 6 11 Note estimate 170.7 100.16 Chand 1760 0 0 1 10 Note estimate 170.7 100.16 Chand 1760 0 0 1 10 Note estimate 170.7 100.16 Chand 1760 0 0 1 10 Note estimate 170.7 100.16 Chand 1760 0 0 1 10 Note estimate 170.7 100.16 Chand 1760 0 0 0 11 Note estimate 170.7 100.16 100.16 Chand 1760 2 1 170.7 Note 160.16 100.16 100.16 100.16 100.16 100.16 100.16 100.16 100.16 100.16 100.16 100.16
SA MeClave RE Taylor	Open 170 0 10 11 Mare entropic 117 Maxe 1356 1 2 2 2 16 10 </td
SA McClave, BE Taylor,	Spectral 0 1 15 Monetann 170 Manu 158 1 2 2 2 2 2 2 1 10
	Sperify 0 0 1 Non-statement (17) Maximum 12 2 3 Non-statement (17) Maximum 12 2 3 Non-statement (17) Non-statement (17) 0 0 14 Non-statement (17) Control 0 0 14 Non-statement (17) Control 0 0 14 Non-statement (17) Control 0 1 12 Non-statement (17)
SA McClave, BE Taylor, RG Martindale	Inc (1) 0 10 <th< td=""></th<>
RG Martindale	Barton 0 0 10 Data Stress Data Stress Control 0 0 10 Data Stress Data Stress Data Stress Control 0 0 10 Data Stress Data Stress Data Stress Control 0 0 10 Data Stress Data Stress Data Stress Control 0 0 10 Data Stress Data Stress Data Stress Control 0 0 10 Data Stress Data Stress Data Stress Control 0 0 10 Data Stress Data Stress Data Stress Control 0 0 10 Data Stress Data Stress Data Stress Control 0 0 10 Data Stress Data Stress Data Stress Data Stress Control 0 0 10 Data Stress Data Stress Data Stress Data Stress Contro 0 0 10 Data Stress
	Specify 0 </td
RG Martindale ASPEN/SCCM	Perform 0 </th
RG Martindale	Herical Distribution 0
RG Martindale ASPEN/SCCM	Marcine 0 </td
RG Martindale ASPEN/SCCM	Particip 0<
RG Martindale ASPEN/SCCM	Marca 0 0 0 0 0 1 <th1< th=""> <th1< th=""> <th1< th=""> <th1< th=""></th1<></th1<></th1<></th1<>
RG Martindale ASPEN/SCCM	Prime 0
RG Martindale ASPEN/SCCM	Marcine 0 </td
RG Martindale ASPEN/SCCM	Marcine 0 0 0 0 1 </td
RG Martindale ASPEN/SCCM	Marcine 1 </td
RG Martindale ASPEN/SCCM	Marcine 0 0 0 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 </td
RG Martindale ASPEN/SCCM CCN Guidelines	
RG Martindale ASPEN/SCCM CCN Guidelines	
RG Martindale ASPEN/SCCM	Marcine 1 </td














Underfeeding Better than Full Feeds: Flawed!


	g BETTER than sibility and Type 1 I		eeding?	
 Braunschweig IN Int %Goal cal 	TACT Study ² ens Rx (n=40) Sta 84.7%	and Rx 55.4%	(n=38) (p<0.0001)	Y
	40.0% LOS, infections, du	16.0% Irat MV	(p=0.02)	Braunschweig
Power analysis	indicated (n=200)	needed	to complete	e study
• Ziegler Example	no plausible mech of Type 1 Error: PN	/Glutan	nine vs PN ir	
	ess infections with 0 total) – More infec			ne
Last 50 pts (15 • Arabi 2011 Single	0 total) – No differe Center Study 1	nce bet	ween groups	5
Un	der 60-70% (n=120)			120)
Received Hosp Mort	59.0%		1.4%	=>














Concept of Nutritional Risk: Nutric Score


Six factors for Nutric Score: Disease severity: Age Initial APACHE II score Initial SOFA score Interleukin-6 Comorbidities Poor nutritional status: Hosp LOS prior to ICU



Identifying critically most from nutrition initial validation of a Data (Hotad ^{SP} , Ronde Dalwa ⁴ , R	therapy: the dev novel risk asses	elopment and
Fable 1: NUTRIC Score variables		
Variable	Range	Points
Age	<50	0
	50 - <75	1
	≥75	2
APACHE II	<15	0
	15 - <20	1
	20-28	2
	≥28	3
SOFA	<6	0
	6 - <10	1
	≥10	2
iumber of Co-morbidities	0-1	0
	>2	1
Days from hospital to ICU admission	0 - <1	0
	≥1	1
	0 - <400	0
L-6		1


Paradigm Shift: Assess Risk-†Therapy-↑Response Observational Studies

- NRS-2002 Jie Study¹ High Risk patients (n=120)with NRS Score ≥ 5 Insufficient (n=77) Sufficient Nutr Rx(n=43) Overall complications 51% → 26% * Nosocomial infection 34% → 16% * No benefit (sufficient vs insufficient) Low Risk pts (n=965) NRS < 5
- Nutric Score Heyland Study² (n=1199) (no Interleukin-6 used)



¹ B Jie (Clin Nutr 2012) ² DK Heyland (Crit Care 2011;15:R268) (Clin Nutr 2015 Jan)

	ndomized rolled Trials RS Score >3)			
Intervent (n=66 Controls (n=66) Johansen Study	Energy 24 kcal/kg* 18 kcal/kg	Protein 1.0 gm/kg* 0.7 gm/kg	19.7%	Re-Hosp 25.7%* 42.4%
Johansen Study				
Intervention	Complic (n=18)	NRS Score 3.4	Hosp LO 14.07d *	






Do Interventional RCTs Support Emphasis on Protein?

Doig Nephro-Protect Trial 1

Unblinded multicenter RCT Pts expected on MV 48 hrs; excluded patients with AKI Short-term IV AAs QD (n=474) Max protein 2.0 gm/kg/d 20 endpoints, 4 subsets No difference in mort, others



• Heyland Protein Top-Up Trial ²

Multicenter RCT adding PN vs placebo to enteral tube feeding Five centers in Europe, US, Canada (n=167) Primary endpoint = 60d mortality; Secondary = LOS, infect, MOF Results from pilot trial – No difference in outcomes between groups

¹ Doig (Int Care Med 2015) ² Heyland (Clinical Trials.gov 2010)

Initiate Enteral Feeding

- EN preferred over PN for nutrition support therapy
- Initiate EN within 24-48 hrs of onset of illness Overt signs of contractility not required to start Absent BS predict intolerance, dz severity, need for vigillence¹



- Initiate EN in the stomach² Divert lower if intolerant, high aspiration risk
- Withhold EN with hemodynamic instability Restart with caution if requiring low dose vasopressor support³

¹Nguyen (J Crit Care 2013;28:537) ² Deane (Crit Care 2013:17:R125) ³ Khalid (Amer J Crit Care 2010;19:261)

• GRVs shou	Monitor T and Ade uld not be used as p Multicenter RCT ² 500cc GRV (n=16	equ part of I GI Co	acy routine c	are ¹	Al Feeds 89% *
200cc	GRV (n=169)	63.	6%	83%	6
Reignier 319 kcal	Multicenter RCT ³ No GRV used (n=2		Infect 16.7%	Mortality 26.4% 2	Deficit 7.8%
509 kcal	Routine GRV (n=2	22)	15.8%	27.0% 2	7.5%
 Focus instance Phys e ¹McClave (JPEN 2 Aspira 	ead on: exam Passing si 016;40:159) ² Montejo (IC at risk Access sil	tool, ga M 2010; te	as Tra 36:1386) ³ R Pro	acking I&Os leignier (JAMA otein calori	2013;309:249) 2 goals

Need for EN in High Risk Patients: Utilize Strategies to Increase EN Delivery

 Compensatory Strategies Over-order calories Timed over 18-20 hrs Volume-based feeding Set catch-up rate



- Multi-Strategy De-escalation (Top-Down or PEP-uP) Start at goal Start with prokinetics Volume-based feed Probiotics (oropharynx and tube) Caloric balance Small peptide formula SB infusion Elevate HOB
- Nurse-driven protocols for EN (Set ramp up, vol, GRV, NPO, etc)
- Alter NPO status for diagnostic tests, procedures, surgery
- Bundle nutrition elements (set of action statements)
 - SA McClave (JPEN 2015;39:707) DK Heyland (CCM 2013;41:2743)

ASPEN/SCCM CCN Guidelines: **Bundle Statements** NEW Guidelines for the Provision and Assessment of Support Therapy in the Adult Critically III Pa of Critical Care Medicine (SCCM) and Ameri American A.S.P.E.N.) TABLE 2. Bundle Statements Assess patients on admission to the ICU for nutrition risk, and calculate both energy and protein goals of nutrition therapy. Initiate enteral nutrition (EN) within 24–48 hours following the onset of critical illness and admission to the ICU and inc goals over the first week of ICU stay. Take steps as needed to reduce risk of aspiration or improve tolerance to gastric feeding (use p infusion, chlorhexidine mouthwash, elevate the head of bed, and divert level of feeding in the ga · Implement enteral feeding protocols with institution-specific strategies to promote delivery of EN. Do not use gastric residual volumes as part of routine care to monitor ICU patients on EN. Start parenteral nutrition early when EN is not feasible or sufficient in high-risk or poorly nourished patients JPEN 2016;40(2):159-211

Formula Selection in the ICU NEW

- Start with standard polymeric isotonic formula (most ICU pts)
- Consider use of specialty formulas Obesity formulas (Class II and III)
- Cannot recommend certain formulas Organ-failure formulas Rarely use hepatic, renal failure Don't use pulmonary failure **Disease-specific (diabetic)**



SA McClave, B Taylor SCCM/ASPEN Guidelines (JPEN 2016;40:159-211)

Immunonutrition and Anti-Inflammatory Formulas

 Elective Surgery, SICU – Use arg/fish oil formula ¹ Infection ↓ 41% (OR=0.59) Hosp LOS ↓2.38 days NEW



- Crit Care MICU Don't recommend arg/FO formula No difference mortality, infection, LOS
- ALI/ARDS No recommendation anti-inflammatory lipid profile formula ²⁻⁸
 - Gadek, Singer, Pontes-Arruda, Grau-Carmona Constant infusion All benefit **Rice ARDSNet, Stapleton**
 - Bolus infusion Harm, no benefit Van Zanten Meta-Plus



- **Constant infusion Harm**
- ¹ JW Drover (JACS 2011;212(3);385) ² JE Gadek (CCM 1999;27:1409) ³ P Singer (CCM 2006;34:1033) ⁴ A Pontes-Arruda (CCM 2006;34:3225) ⁵ T Grau-Carmona (Clin Nutr 2011;30:578) ⁶ T Rice (JAMA 2012;307:795) ⁷ R Stapleton (CCM 2011;39:1655) ⁸ A Van Zanten (JAMA 2014;312:514)

Probiotics – Use for select patien Where RCTs have shown sa	NEW
Do not use routinely for ger	
	McClave, Taylor, Martindale (SCCM ASPEN 2016 Guideline
Antioxidants – Use for all pts red	uiring Specialized Nutr Support

¹Zhang (World J Gastro 2010;16:3970)

What is the Role of PN in the ICU?




Exclusive PN Can Be Done Safely

Doig Early PN Study ICU Pts with Short Term EN Contraindication


- Early PN in Pts not expected to get EN for 3 days (n=1372) Multicenter PRCT PN vs STD
- Results: Durat MV shorter in PN by 0.47 d * Trend less ICU LOS by 0.8 d No different – Mortality, infection, QOL, hosp LOS, function
- Conclusion: PN can be given safely early on Little benefit realized

Doig GS, Simpson F (JAMA 2013;309:2130)

Supplemental PN Can Be Done Safely



CP Heiddeger, M Berger, C Pichard (Lancet 2012 Dec 3)



SE Harvey CALORIES Trial Group (NEJM Ahead of Print 10-1-14)

Nutrition • Exclusive PN Low Risk - Withhold exclusive PN



Use of Parenteral

- if EN not feasible (NRS 2002 ≤ 3 or Nutric Score ≤5) High Risk - Initiate exclusive PN ASAP (esp malnourished) if EN not feasible (NRS 2002 ≥5, Nutric Score ≥6)
- Supplemental PN Add after 7-10d if EN < 60% goal high or low risk 1

Maximize efficacy of PN

- Use Multidisciplinary Nutrition Team, protocols Hypocaloric dosing (80%) first week ² Withhold soy-based lipids first week
 - Moderate glucose control (140-180 mg/dL)
 - Transition off PN when EN provides > 60% goal

¹Heiddeger (Lancet 2012 Dec 3) ² Jiang (Clin Nutrit 2011;30:730)

Summary



- Benefit of nutrition Rx derived from provision of early EN
- Standard polymeric formula appropriate for majority
- Use PN earlier in high risk than low risk pts when EN not feasible
- Appropriate monitors to assure safety, tolerance
- Interpret guidelines as they apply to institutional pt populations

Thank You!!

NLC



CEU/CPE Instructions

DINLC

- To receive your CEU/CPE Certificate:
- 1. Go to www.NutriciaLearningCenter.com
- 2. Click on "CE Credit Request"
- 3. Enter code: EWCCN3

4. Certificate will be visible for download on your NLC personalized dashboard

